1. Pink Sheet
  3. >>US FDA Performance Tracker

Novo’s Insulin Icodec Hypoglycemia Risk Outweighs Limited Benefit In Type 1 Diabetes–FDA Panel

 
• By Sue Sutter

The Endocrinologic and Metabolic Drugs Advisory Committee majority says new studies should validate the proposed risk mitigation measures before approval for T1D.

Scales
The risks of insulin icodec outweigh its benefits in type 1 diabetes, the adcomm said. • Source: Shutterstock

Novo Nordisk A/S should conduct more studies before its long-acting insulin icodec can be approved for use in type 1 diabetics, a majority of US Food and Drug Administration advisory committee members said on 24 May.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers